- Home
- NVCT vs SWKH Comparison
NVCT vs SWKH Comparison
Compare NVCT & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | SWKH |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 205.9M |
| IPO Year | 2022 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NVCT | SWKH |
|---|---|---|
| Price | $7.64 | $17.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $15.33 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 87.9K | 11.1K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | N/A | ★ $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.24 |
| Revenue Growth | N/A | ★ 62.38 |
| 52 Week Low | $5.03 | $13.17 |
| 52 Week High | $11.52 | $20.49 |
Technical Indicators
Market Signals| Indicator | NVCT | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 52.31 |
| Support Level | $7.57 | $17.00 |
| Resistance Level | $7.91 | $17.30 |
| Average True Range (ATR) | 0.38 | 0.24 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 33.76 | 30.28 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.